Seeking Partners in Development
EmeraMed is seeking strategic partners and investors to support the continued clinical development and potential commercialization of Emeramide (also known as NBMI or Irminix®). Emeramide is designed to bind irreversibly to certain heavy metals (such as mercury, arsenic, cadmium, lead, and others) and to address oxidative stress.
The Toxic Journey of Mercury Vapor: Absorption, Oxidation, and Cellular Trapping
How inhaled mercury vapor enters the body, crosses the blood-brain barrier, and becomes trapped in cells — an in-depth look at the mechanisms of mercury vapor toxicity.
Emeramide (NBMI): Mercury Chelator Under FDA Review
Emeramide (Also known as Irminix®) is a lipophilic mercury chelator in development by EmeraMed, that is currently under FDA review as a treatment for mercury poisoning.
Warning: Counterfeit Emeramide sold illegally in EU & USA
Counterfeit Emeramide is being sold under our various trade names (OSR#1, NBMI, Emeramide) and tests have shown that it is not Emeramide. This is unsafe and illegal and we are continuously in contact with various regulatory authorities to take action.
Clinical Trials
The most current, up-to-date information on our clinical trials.
Pilot Study Results: Emeramide (NBMI) in Mercury-Exposed Gold Miners in Zaruma Ecuador
Discover results from a pilot study of NBMI (Emeramide) in mercury-exposed gold miners in Zaruma, Ecuador. The 300 mg/day group showed significant reduction in physical fatigue and promising improvements in symptoms and urinary mercury levels despite ongoing exposure.